BMY posts
FeedPosted Oct 9th 2009 11:50AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Viacom (VIA), JPMorgan Chase (JPM), Bristol-Myers Squibb (BMY), Dean Foods (DF), Research in Motion (RIMM), Starwood Hotels Worldwide (HOT), Marriott Intl'A' (MAR), Analyst initiations
Analyst upgrades:
- Piper Jaffray upgraded Viacom (NYSE:VIA) to Overweight from Neutral to reflect the improving ad market and better ratings at key cable networks. The firm raised its target on shares to $35 from $29.
- Baird upgraded Research in Motion (NASDAQ:RIMM) to Outperform from Neutral on valuation as it views the recent weakness as a buying opportunity. The firm keeps an $84 price target on shares.
- Jefferies upgraded Usana (NASDAQ:USNA) to Buy from Hold as it believes direct selling companies have been gaining momentum. The firm raised its target on shares to $44 from $37.
- AK Steel (NYSE:AKS) was upgraded to Buy from Hold at Deutsche Bank.
- First Merit (NASDAQ:FMER) was upgraded to Perform from Underperform at Oppenheimer.
- Spectra Energy (NYSE:SE) was upgraded to Conviction Buy from Neutral at Goldman.
Continue reading Analyst upgrades, downgrades and initiations: VIA, RIMM, ARO, JPM, BMY
Posted Aug 28th 2009 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Analyst initiations
Analyst upgrades:
- Pacific Sunwear (NASDAQ: PSUN) was upgraded to Buy from Neutral by Pali Capital, which cited low expectations, new CEO experience, and compelling risk/reward for the upgrade.
- RBC Capital raised Aruba Networks (NASDAQ: ARUN) to Outperform from Sector Perform, based on increased visibility into wireless networking products.
- J. Crew (NYSE: JCG) was upgraded to Hold from Underperform by Needham after the company reported better-than-expected Q2 report and guidance.
- RBC Capital raised Lundin Mining (NYSE: LMC) to Outperform from Sector Perform, citing updated copper forecasts and valuation.
- Netezza (NYSE: NZ) was upgraded to Buy from Accumulate by ThinkEquity.
- Sanofi-Aventis (NYSE: SNY) was raised to Overweight from Neutral by JPMorgan.
- Williams-Sonoma (NYSE: WSM) was upgraded to Buy from Neutral by Goldman.
- Network Engines (NASDAQ: NENG) was raised to Buy from Hold by Cantor.
Continue reading Analyst upgrades, downgrades and initiations: BP, DIS, JCG, MOS, POT, PSUN ...
Posted Aug 19th 2009 10:00AM by Jim Cramer (RSS feed)
Filed under: Apple Inc (AAPL), Ford Motor (F), Exxon Mobil (XOM), China, Market matters, Citigroup Inc. (C), Target Corp. (TGT), BB and T (BBT), Bristol-Myers Squibb (BMY), Wendy's Intl (WEN), BHP Billiton Ltd ADR (BHP), Freep't McMoRan Copper (FCX), Stocks to Buy, Union Pacific Corporation (UNP), Cramer on BloggingStocks, Potash Corp. of Saskatchewan (POT)
TheStreet.com's Jim Cramer says even stocks without exposure to that country will probably be on sale today. If China has pulled back 20%, do we have to pull back 20%, even though they were up 80% and we are up 9%? Are we so in lock step now that when China catches a cold, we are the ones with pneumonia?
I don't think so. It's such an easy story to stretch out, though you can see that our
Freeports (NYSE:
FCX) (
Cramer's Take) and our
Exxons (NYSE:
XOM) (
Cramer's Take) can get hammered.
Continue reading Cramer on BloggingStocks: China-led drop offers a time to buy
Posted Jul 27th 2009 10:00AM by Jim Cramer (RSS feed)
Filed under: Pfizer (PFE), Market matters, Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Stocks to Buy, Cramer on BloggingStocks
TheStreet.com's Jim Cramer says health care has never been this cheap relative to the market in its history. Health care's not done rallying. As President Obama prepared himself for claiming a great political victory, we are all recognizing that the single-payer, socialized medicine covering cradle-to-grave, 100% paid for by the rich, the fear that left all things health care in the P/E dustbin, is dead. That's not going to happen.
That leaves us with the biggest bargains the market has to offer.
Health care has never been this lowly valued relative to the market in its history. Remember, 98% of the time it trades at a meaningful premium. I think that many believe some of these moves (like the
Celgene (NASDAQ:
CELG) (
Cramer's Take) move) is because of gigantic new drug finds. In fact, I think they just got too cheap and the only thing really meaningful about the Celgene rally came because one of its Revlimid studies was stopped for good results, actually a predictable event given how well the drug works on many different kinds of cancers.
Continue reading Cramer on BloggingStocks: The health care bargain
Posted Jun 1st 2009 1:50PM by Melly Alazraki (RSS feed)
Filed under: Deals, Rumors, Bristol-Myers Squibb (BMY)

If you've been following
Elan Corp. (NYSE:
ELN) lately, you've probably come to take any story of a deal, takeover, sale with a grain of salt.
This morning, Elan shares soared over 16% after stories on
Reuters and the
Wall Street Journal over the weekend said it is in advanced talks to sell a minority stake to
Bristol-Myers Squibb (NYSE:
BMY).
Moreover, Elan was said to be in talks with a second suitor, but the status of those discussions was unclear. This, Reuters reported, could be the first move in a multi-step transaction to sell Elan outright.
While the shares are still up a healthy 12% by midday, now Bloomberg reports that according to UBS analysts,
Bristol isn't in talks to buy a stake in Elan.
Continue reading Elan: Yet another deal rumor -- Bristol eyeing a stake
Posted May 2nd 2009 2:40PM by Trey Thoelcke (RSS feed)
Filed under: Earnings reports, Time Warner (TWX), Pfizer (PFE), Motorola (MOT), Exxon Mobil (XOM), Viacom (VIA), Revlon (REV), Netflix, Inc. (NFLX), Bristol-Myers Squibb (BMY), Domino's Pizza (DPZ), Procter and Gamble (PG), U.S. Steel (X), Under Armour'A' (UA), E*TRADE (ETFC)
Here are some highlights from this past week's earnings coverage from BloggingStocks:
Continue reading Earnings highlights: P&G, DreamWorks, E*Trade, Netflix, Under Armour, Humana and more
Posted Apr 28th 2009 10:10AM by Mark Fightmaster (RSS feed)
Filed under: Earnings reports, Bristol-Myers Squibb (BMY)

Pharmaceutical firm
Bristol-Myers Squibb (NYSE:
BMY) announced that strong sales of Plavix and Abilify (an anti-clotting and psychiatric drug, respectively) helped
boost the company's quarterly revenue. The boost wasn't enough though, as higher taxes and a litigation charge weighed on the company's profit, pulling it 3.5% lower.
BMY's quarterly earnings totaled 32 cents per share, a penny worse than a year ago. However, earnings excluding items would have been 48 cents per share (simple math tells me that the charges were 16 cents per share). These charges included a litigation charge that helped settle a shareholder lawsuit. Quarterly revenue checked in at $5.02 billion, which was 3% higher than the first quarter of 2007. Excluding the effects of the strong dollar, BMY's sales would have increased 8%. Expectations called for higher sales of $5.13 billion, but lower per-share earnings of 47 cents per share.
Continue reading Bristol-Myers' first-quarter earnings fall
Posted Feb 11th 2009 12:20PM by Tom Taulli (RSS feed)
Filed under: Citigroup Inc. (C), Bristol-Myers Squibb (BMY), Morgan Stanley (MS)
This week, there was some hope that we might see signs of relief in the IPO market. But, with the massive sell-off yesterday, those hopes are dimmed.
Yet, there was one deal that was able to get off the ground: Mead Johnson Nutrition (NYSE: MJN). The company, which has been a part of Bristol-Myers Squibb Co. (NYSE: BMY) since 1967, is a leader in the baby formula business.
Mead was able to price its IPO at $24, which was at the top-end of its $21-$24 round. In all, the company issued 30 million shares.
No doubt, Mead is a solid company, with about $2.6 billion in sales (last year). The company has a portfolio of over 70 products that are distributed across 50 countries.
Continue reading Mead Johnson braves the treacherous IPO waters
Posted Feb 11th 2009 8:17AM by Melly Alazraki (RSS feed)
Filed under: Earnings reports, Sirius Satellite Radio (SIRI), Citigroup Inc. (C), JPMorgan Chase (JPM), Applied Materials (AMAT), Bank of America (BAC), Bristol-Myers Squibb (BMY), Dean Foods (DF), Research in Motion (RIMM), Goldman Sachs Group (GS), NIKE, Inc'B' (NKE), Activision Inc (ATVI), Rio Tinto plc ADS (RTP), Initial public offerings
Before the bell: Stocks to rebound, but investors remain cautious
ArcelorMittal (NYSE: MT) swung to a
surprising $2.6 billion loss in the fourth quarter -- its first ever -- as it experienced a collapse in demand and a sharp drop in prices. It wrote down $4.4 billion in pre-tax charges. The steel giant is also shedding some 9,000 workers. MT shares jumped over 6% in premarket trade.
Applied Materials (NASDAQ: AMAT) warned late Tuesday that chipmakers will spend 50% less this year for its products. The maker of semiconductor production equipment also posted a
fiscal first-quarter loss of $3 million, excluding charges, and said it will cut 14% of its workforce, or about 2,000 jobs, as well as production. AMAT shares declined some 2% in premarket trade.
Continue reading Stocks in the news: MT, AMAT, NVDA, MJN, SIRI, CS, DF, NKE, RIMM, RTP ...
Posted Feb 1st 2009 9:40AM by Trey Thoelcke (RSS feed)
Filed under: Earnings reports, Yahoo! (YHOO), Pfizer (PFE), Home Depot (HD), McDonald's (MCD), American Express (AXP), Best Buy (BBY), Bristol-Myers Squibb (BMY), Colgate-Palmolive (CL), Texas Instruments (TXN), Valero Energy (VLO), Eaton Corp (ETN), Delta Air Lines (DAL)
Here are some highlights from this past week's earnings coverage from BloggingStocks:
Continue reading Earnings highlights: Yahoo!, McDonald's, American Express, Pfizer, Delta and others
Posted Jan 27th 2009 2:00PM by Brent Archer (RSS feed)
Filed under: Major movement, Earnings reports, Good news, Bristol-Myers Squibb (BMY), Options, Technical Analysis
Bristol-Myers Squibb (NYSE:
BMY -
option chain) shares are headed higher today after the company said its
fourth-quarter profit came in at $1.24 billion, or 63 cents per share, on revenue of $5.25 billion.
BMY's adjusted profit of 46 cents per share easily beat analysts' projections of 41 cents per share. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on BMY.
BMY opened this morning at $22.92. So far today the stock has hit a low of $22.72 and a high of $23.44. As of 12:05, BMY is trading at $23.39, up 1.14 (5.1%). The chart for BMY looks bullish and
S&P gives BMY a positive 4 STARS (out of 5) buy ranking.
Continue reading Bristol-Myers (BMY) posts Q4 earnings above targets
Posted Jan 27th 2009 10:55AM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Caterpillar (CAT), American Express (AXP), Bristol-Myers Squibb (BMY), Analyst initiations
Analyst upgrades:
- Societe Generale upgraded shares of Veolia Environment (NYSE: VE) to Buy from Hold as they believe the company's new finance chief implement additional cost savings.
- Citigroup upgraded shares of Sun Healthcare (NASDAQ: SUNH) to Buy from Hold and added the stock to their Top Picks Live List as they believe the market is pricing in a more severe Medicaid and Medicare reimbursement outlook than is probable. The firm has a $14 target on the stock.
- Calyon believes in 2010, American Express (NYSE: AXP) will have easy comps, reserve releases, and income statement leverage. The firm upgraded shares to Outperform from Underperform.
- Societe Generale (OTC: SCGLY) was upgraded to Buy from Hold at Citigroup.
- Caterpillar (NYSE: CAT) was raised to neutral from Sell at UBS.
- Goldman upgraded Biogen Idec (NASDAQ: BIIB) to Buy from Neutral and added shares to the Conviction Buy List; Goldman also added Bristol-Myers (NYSE: BMY) to the Conviction Buy List.
Continue reading Analyst upgrades, downgrades and initiations: AXP, CAT, BMY, GNK, TXCO ...
Next Page >